posted on 2023-03-31, 16:04authored byIngrid A. Mayer, Carlos L. Arteaga
Related Article from Does Lapatinib Work against HER2-negative Breast Cancers?
History
ARTICLE ABSTRACT
Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers. Clin Cancer Res; 16(5); 1355–7